VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant testing methods across its oncology research programs, a strategic shift that could significantly enhance the predictive value of preclinical data and reduce reliance on animal models in cancer drug development. The Switzerland-based company, with a key financial and regulatory presence in the U.S., announced on October 7, 2026, that it is implementing New Approach Methodologies (NAMs), a collection of non-animal techniques including cell-based assays and computational modeling, according to a company announcement covered by NEWMEDIAWIRE.
The move matters because traditional animal testing often fails to accurately predict human responses, contributing to high attrition rates in oncology clinical trials. By aligning with FDA-endorsed NAMs, VERAXA aims to generate more clinically informative data while reducing the number of animals required for drug development. The strategy supports the company’s pipeline of BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates for cancer treatment.
New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. In one ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, only about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This efficiency could accelerate preclinical timelines and lower costs, making the approach attractive to investors and partners focused on rapid, translatable drug development.
VERAXA’s emphasis on human-relevant testing also positions it within a broader regulatory trend. The FDA has been encouraging the adoption of NAMs to modernize drug development, and companies that successfully integrate these methods may gain a competitive edge in designing trials and securing approvals. For VERAXA, the strategy is not merely a cost-saving measure but a core component of its effort to advance antibody-based cancer therapies with greater confidence in their clinical potential.
As a smaller biotechnology company, VERAXA’s ability to generate robust preclinical data efficiently could enhance its appeal for partnerships or licensing deals. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Detailed terms of use and disclaimers applicable to all content provided by IBN are available at https://IBN.ai/Disclaimer.
